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a Saudi ArabiaBackground: Hepatocellular carcinoma (HCC) is a common malignancy and the most frequent sites of metastasis
include lungs, bone, lymphatic, and brain, however, Intra-cardiac involvement rarely develops in patients with HCC
and it has poor prognosis. The clinical course may be complicated by many fatal cardiovascular complications. Absence
of cardiac symptoms, however, is an unusual condition.
Case report: We reported a rare case of hepatocellular carcinoma with large invasion into the right atrium and no
cardiac symptoms.
Conclusion: Cardiac metastases occur in 10% of all cancer patients. Heart involvement should be suspected in all
patients.
 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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Cardiac tumors are a rare entity, comprised oftumors with diverse histology and natural
history [1]. Cardiac tumors are classified into pri-
mary benign or malignant tumors that arise from
the heart or into secondary, metastatic tumors that
invade the heart. Primary cardiac tumors occur
with a low incidence. It is estimated that second-
ary tumors are a hundred times more common
than primary cardiac lesions [1–3].Malignant tumors of various organs and tissues,
originating from all over the body, may dissemi-
nate to the right atrium (RA) by a nodular embolus
and rarely by direct extension. Current literature
reports that malignant tumors, such as HCC,
pancreatic carcinoma, adrenal carcinoma, testicu-
lar cancer, lymphoma, leiomyosarcoma, nasopha-
ryngeal cancer, esophageal cancer, Ewing’s
sarcoma and Wilm’s tumor can encroach on the
RA [4]. Portal vein (PV), hepatic vein (HV), and
the inferior vena cava (IVC) are often affected.
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WITH HEPATOCELLULAR CARCINOMA: CASE
REPORT AND LITERATURE REVIEWOn the other hand, HCC ranks as the eighth
most common cancer, fifth among males and
seventh among females [5]. In fact, HCC is the
commonest primary tumor of the liver [6]. The
highest incidence rates were in developing coun-
tries where infection with hepatitis B virus (HBV)
is common [5]. Moreover, liver cancer is consid-
ered to be the third leading cause of cancer death
with an estimated more than half a million deaths
in 2007 [7]. The usual sites of HCC metastasis are
lung, bone, and lymphnode [8]. However, cardiac
metastasis from HCC is rare [9].
This case report demonstrates an unusual
metastasis of HCC as a large mass in the right at-
rium of a patient diagnosed with Hepatitis B.Case report
In September 2012, a 70-year-old gentleman
known to have Hypertension and hepatitis B virus
carrier, most likely from remote blood transfusion
more than 30 years ago, presented to the emer-
gency department with history of right upper
quadrant abdominal pain for 2 months, which
was dull in nature, intermittent, with no specificFigure 1. (A) CT scan of abdomen shows the hepatic mass. (B) CT scan
extension of the tumor to RA (see arrows).aggravating or reliving factors. This was associ-
ated with decreased appetite and weight loss.
There were no nausea, vomiting, melena, hema-
temesis, dysphagia or fever. Patient denied any
cardiac symptoms in form of shortness of breath,
chest pain, orthopnea and PND. On physical
exam, the patient looked cachectic, he was con-
scious, well oriented, not pale or jaundiced with
no signs of chronic liver disease. Cardiac examina-
tion revealed normal heart sounds, abdomen was
soft with liver span of 18 cm and palpable epigas-
tric mass measured 6  6 cm not separable from
the liver with no tenderness or ascites. No lower
limb edema.Laboratory findings were as follows
White cell count (WCC): 2.70/mm3; hemoglobin
(Hb): 13.3 mg/dL; platelet (Plt): 76,000/mm3; ESR
95 mm/h PT: 15.7 s; International normalized ratio
(INR):1.23; total protein: 83 g/L; albumin: 27 g/L;
aspartate aminotransferase (AST): 93 IU/L (N:
12–37); alanine transaminase (ALT): 54 IU/L (N:
20–65); ALP: 110 IU/L (N: 50–136); GGT: 75 IU/L
(N:15–85); total bilirubin: 21 lmol/L (N: 3–117),of chest shows the Right atrial mass. (C) Coronal CT showing the
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surface antigen was positive. Serological markers
of hepatitis C were negative. Alpha feto protein
(AFP): 212.5 KIU/L (N: 0–5.8). Electrocardiogram
(EKG) was normal and Chest X-ray (CXR) showed
small nodules bilaterally suggestive of metastasis.
Imaging study
Ultrasound Abdomen: The liver was enlarged with
coarse parenchyma together with multiple large
solid hypoechoic hepatic mass lesions seen in
both right and left lobes, from which the largest
was located in the left lobe. Bulky spleen and asce-
tic fluid were observed in the abdominal and pel-
vic cavity. Bones scan showed no evidence of
metastatic lesion.
CT scan of chest, abdomen and pelvis
Multiple hypervascular hepatic lesions with ra-
pid wash out associated with multiple pulmonary
nodules and significant abdominal lymphadenop-Figure 2. (A) TTE showing four-chamber view with a large right atrium
revealing a large RA mass extending to the inferior vena cava (IVC).
Figure 3. TEE is showing a large lobular mass (9  7 cm in diameter (A) (
(B).athy were shown as well as large Right atrial
lesion extending into the proximal IVC and
hepatic veins (Fig. 1) suggesting direct intravascu-
lar extension of the HCC to the right atrium.
However, HCC in non-cirrhotic liver parenchyma
with multiple metastases was also a possibility.Transthoracic echocardiogram (TTE)
A large mass was shown in the right atrium
seems to be extending to or originating from the
inferior vena cava (IVC) Fig. 2B. Normal left and
right ventricles systolic function. Normal left and
Right atria size. No significant valve pathology
seen.Transesophageal echocardiogram (TEE)
Revealed a large Right atrial mass, occupying al-
most the whole right atrium and extending into
the IVC. A spontaneous contrast seen in the IVC
distal to the mass.mass filling (arrow) most of the right atrium. (B) Sub costal view
arrow) occupying almost the whole right atrium extending to the IVC
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A LARGE RIGHT ATRIAL MASS IN A PATIENT
WITH HEPATOCELLULAR CARCINOMA: CASE
REPORT AND LITERATURE REVIEWThe mass was vascular, lobular with small mo-
bile component; the echo picture was suggestive
of a vascular malignant tumor with no extension
to the pulmonary artery. The mass did not pro-
trude to right ventricle (RV) and did not cause
RV inflow obstruction (Fig. 3A).
CT-guided liver biopsy was done and
histopathology
CT-guided liver biopsy was done and histopa-
thology of the lesion came to be consistent with
a moderately differentiated hepatocellular
carcinoma.
Treatment and course
Patient was reviewed by medical oncology team
and started on Nexavar (sorafinib), he had poor
tolerance with on-going thrombocytpenia and
died 2 months later with sepsis complicated by
multi-organ failure. No symptoms of CHF were
present even at later stage.Discussion
Worldwide, the prevalence of HCC is estimated
to be about 180 million people and the incidence
continues to rise annually [10]. The majority of
HCC arises from viral hepatitis. In the U.S., 16%
of HCC are attributed to HBV and 48% to HCV
[10]. HBV-related HCC, tend to develop 25–
30 years after chronic infection [11].
Various cardiac symptoms or findings such as
sudden dyspnea, massive lower extremity edema,
sudden death, or dilatation of the jugular veins are
generally seen in HCC patients with intracardiac
involvement. [1,2].
HCC metastases tend to spread through intra-
hepatic blood vessels, lymphatics, or direct infil-
tration. It is known to have a marked propensity
for vascular invasion and extension. Hematoge-
nous extension may be result of hepatic, portal
veins or vena cava involvement and this appears
to have been the route of metastasis in the patient
reported here. In a study of 439 HCC autopsied
cases, intra-atrial tumor growth was found in 18
cases. Moreover, continuous tumor thrombus
involving the RA, IVC and the hepatic vein was
seen in 15 cases. Tricuspid valve was crossed
entering the right ventricle in 5 cases [16]. The
mechanism of cardiac involvement is related to
the tendency of this tumor to invade the vena
cava, thus easily reaching the cardiac cavities. In
spite of this fact cardiac metastasis is still consid-
ered an unusual presentation of HCC. Cardiacsymptoms may be insignificant as evident in this
reported case. The most common symptoms of
cardiac metastasis reported in one study included:
asymptomatic in 39.5%, bilateral lower leg edema
in 37.5% and exertional dyspnea in 31.3% [17].
Advanced HCC is a disease with poor prognosis
and median survival time of 4 to 7 months [12]. Ex-
tra hepatic metastasis of HCC may reach around
18% and the most common sites of involvement
are: lungs, lymph nodes, adrenal glands, and
bones [13]. Intracardiac involvement rarely occurs
in patients with HCC and its frequency was found
around 2% in various series [2]. The prognosis of
HCC with intracardiac involvement is poor, with
a median survival range of 1–4 months [14]. The
risk for cardiopulmonary collapse is high in such
patients. Possible cardiopulmonary complications
include heart failure, tricuspid stenosis or insuffi-
ciency, ventricular outflow tract obstruction, sud-
den cardiac death, secondary Budd–Chiari
syndrome, pulmonary embolism, and pulmonary
metastasis [15].
It was reported that the mean survival time from
the time of diagnosis of cardiac metastasis was
161 days and the main reason of mortality was re-
lated to HCC. Only few patients expired because
of cardiac metastases [17].
Yusuf SW and his colleagues reported the clini-
cal characteristics, echocardiograhic findings,
therapy and outcome of 59 patients with primary
and metastatic cardiac tumors. Their institutional
echocardiogram database from 1993 through
2005 was reviewed to identify patients diagnosed
with intra-cardiac tumor. For both primary and
secondary tumors, dyspnea was the most common
symptom and right atrium was most frequently
involved. Sarcoma was the most common primary
cardiac tumor while metastasis from renal cell car-
cinoma was the most common secondary tumor
[1].
Multidisciplinary treatments to control the
growth of HCC offer patients with cardiac involve-
ment a useful chance of cure. However, such ther-
apeutic modalities may not be feasible especially
if the patient has a poor general performance,
metastatic disease or underlying hepatic dysfunc-
tion [14]. This explains the management plan ap-
plied on this patient here who was given
sorafinib, which is usually given for such ad-
vanced cases and proved to prolong survival in
such population [18].
In conclusion, this case report alerts physicians
to HCC patients with cardiac metastasis and
based on the above mentioned literature data,
we suggest that heart involvement should be sus-
C
A
SE R
EPO
RT
178 ALBACKR
A LARGE RIGHT ATRIAL MASS IN A PATIENT
WITH HEPATOCELLULAR CARCINOMA: CASE
REPORT AND LITERATURE REVIEW
J Saudi Heart Assoc
2014;26:174–178pected in all HCC patients and probably a screen-
ing TTE may be done even in absence of any car-
diac manifestations. This is important since HBV
infection is endemic and prevalent in Saudi Ara-
bia ranging from 3% to 6% [19]. To our knowledge,
our patient seems to be the third reported case
with HCC metastasis in Saudi Arabia. Interest-
ingly this patient despite the large size of the RA
mass was asymptomatic from cardiac point of
view, unlike other reported cases with a compara-
ble size of tumor [1].Acknowledgement
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